PD-1/PD-L1 blocking immunotherapy not only impacts cytotoxic T cells and cancer cells but also affects multiple targets among tumor-infiltrating immune cells, which collectively define the dynamic balance of the tumor immune system. This evidence concerns the gene CD274 and cancer.